Ae­glea Bio­Ther­a­peu­tics to re­duce head­count to 10, seek strate­gic al­ter­na­tives

Ae­glea Bio­Ther­a­peu­tics rolled out in­ter­im da­ta for its drug for a rare in­her­it­ed dis­or­der, but said it doesn’t sup­port a piv­otal tri­al de­sign as the biotech will lay off more em­ploy­ees and seek a merg­er or oth­er trans­ac­tion.

On Wednes­day, the Austin, TX-based pen­ny stock lift­ed the veil on the in­ter­im re­sults from an on­go­ing Phase I/II tri­al of peg­tarvil­iase, a drug meant to re­duce lev­els of the amino acid ho­mo­cys­teine to treat clas­si­cal ho­mo­cystin­uria, a rare con­di­tion where the body can­not process ho­mo­cys­teine, caus­ing it to build up and con­tribute to dis­ease-re­lat­ed com­pli­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER